How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) released its earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.54). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.25 million.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT) , Alector (ALEC) , Gossamer Bio (GOSS) , Precision BioSciences (DTIL) , Fulcrum Therapeutics (FULC) , LogicBio Therapeutics (LOGC) , Homology Medicines (FIXX) , NVIDIA (NVDA) , Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK) .

When did Kaleido Biosciences IPO?

Kaleido Biosciences (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free KLDO Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 935 shs
Average Volume: 4,361 shs
Market Capitalization: $4,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines SEC Filings Social Media

Get Kaleido Biosciences alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Kaleido Biosciences Stock (NASDAQ:KLDO)

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

KLDO Stock News Headlines

April 5, 2024 | fool.com

Kaleido Biosciences (OTC: KLDO)

April 4, 2024 | finance.yahoo.com

Kaleido and Emma Join Forces to Help Families Secure Their Financial Future: An Innovative Partnership

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 2, 2024 | finance.yahoo.com

Change in management Kaleido IDEO+ individual RESP portfolios

December 20, 2023 | finance.yahoo.com

Mobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido Intelligence

December 20, 2023 | finanznachrichten.de

KALEIDO INTELLIGENCE LIMITED: Mobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido Intelligence

December 14, 2023 | finance.yahoo.com

Kaleido Intelligence to Launch Huge Enterprise Connectivity Survey in 2024

November 22, 2023 | finanznachrichten.de

ViCentra: Kaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetes

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 14, 2023 | finance.yahoo.com

Eseye, G+D, Thales and Vodafone Recognised as Champion Connectivity Vendors by Kaleido Intelligence

November 7, 2023 | bizjournals.com

Local tech startup brings augmented reality to art market

November 5, 2023 | morningstar.com

Kaleido Biosciences Inc KLDO

October 24, 2023 | finance.yahoo.com

Nokia and NTT DATA Recognised as Champion Private Network Vendors by Kaleido Intelligence

October 16, 2023 | tmcnet.com

Syniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Third Straight Year

October 12, 2023 | finanznachrichten.de

BroadForward earns top rating from Kaleido for BroadForward Signaling Security and Firewall products

October 10, 2023 | finanznachrichten.de

KALEIDO INTELLIGENCE LIMITED: BICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido Intelligence

October 10, 2023 | finance.yahoo.com

BICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido Intelligence

September 13, 2023 | msn.com

Kaleido Family Arts Festival crowdfunding after grant cuts leave it $50K short

August 26, 2023 | seekingalpha.com

IDXG Interpace Biosciences, Inc.

August 21, 2023 | tmcnet.com

eSIM/iSIM Shipments to Exceed 1.4 Billion in 2028, Propelled by Ecosystem Simplification: Kaleido Intelligence

August 6, 2023 | finance.yahoo.com

KLDO - Kaleido Biosciences, Inc.

June 20, 2023 | technews.tmcnet.com

IoT Wholesale Roaming Revenue to Exceed $8 Billion in 2028: Kaleido Intelligence

June 3, 2023 | benzinga.com

Kaleido Creative Studio Launches OnNiche™: A Niche-Based Marketing System for Financial Advisors

April 26, 2023 | finanznachrichten.de

KALEIDO INTELLIGENCE LIMITED: Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028

April 26, 2023 | tmcnet.com

Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028

March 28, 2023 | marketwatch.com

Consumer & IoT Mobile Roaming Data Traffic Expected to Triple 2019 Volume, Approaching 3,000 Petabytes in 2023: Kaleido Intelligence

February 22, 2023 | yahoo.com

Direct-To-Satellite Communications to Generate $9 Billion in Airtime Revenues for Operators in 2030: Kaleido Intelligence

See More Headlines

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:KLDO
CUSIP: N/A
CIK: 1751299
Web: www.kaleido.com
Phone: (617) 674-9000
Fax: N/A
Employees: 76
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $1.10 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 42,623,000
Free Float: 38,787,000
Market Cap: $4,000.00
Optionable: Not Optionable
Beta: -0.06

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Kimberly Hocknell
Senior Vice President of Technical Operations
Dr. Mark A. Wingertzahn Ph.D. (Age 52)
Senior VP of R&D and Head of Development

Key Competitors

View All Competitors

KLDO Stock Analysis - Frequently Asked Questions

How were Kaleido Biosciences' earnings last quarter?: Kaleido Biosciences, Inc. (NASDAQ:KLDO) released its earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.54). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.25 million.
What other stocks do shareholders of Kaleido Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).
When did Kaleido Biosciences IPO?: Kaleido Biosciences (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of Kaleido Biosciences?: Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KLDO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial